Ganesh Kumar
Jul 8 · 3 min read

According to the latest report published by Credence Research, Inc. “Non-Invasive Prenatal Testing Market by Products (MaterniT21 PLUS, BambniTest, informaSeq Prenatal Test, Harmony Prenatal Test, Non-invasive Fetal Trisomy (NIFTY) Test, Verifi, PrenaTest, Panorama Test, VisibiliT Test) — Growth, Share, Opportunities & Competitive Analysis, 2016–2022,” the non-invasive prenatal testing market was valued at USD 613.0 Mn in 2015, and is expected to reach USD 1,939.9 Mn by 2022, expanding at a CAGR of 17.9% from 2016 to 2022.

Market Insights

The global non-invasive prenatal tests (NIPT) market is experiencing a double-digit growth facilitated by market drivers such as rise in average maternity age, growing incidence of chromosomal abnormalities that demand early and non-invasive detection. Other major factor that aids to the growth of this market is rise in healthcare expenditure.

Browse the full report at https://www.credenceresearch.com/report/non-invasive-prenatal-testing-market

Non-invasive prenatal testing is defined as a highly sensitive screening process that assists in detecting chromosomal abnormalities in the fetus during pregnancy. Some of such chromosomal abnormal abilities that can be detected through NIPT are Down syndrome, Patau syndrome, Edwards’ syndrome and Turner syndrome.

Among the available NIPT tests, the MaternitT21 test is the largest segment and it is anticipated that its dominance will continue through 2022. It was the first test to receive approval for detection of Trisomy 21 in 2011. Other chromosomal abnormalities that could be detected with MaternitT21 are Wolf-Hirschhorn syndrome, DiGeorge syndrome, Langer-Giedion syndrome, 1q36 deletion syndrome and Jaconsen syndrome. MaterniT21 used cfDNA and parallel sequencing technology and delivers results in a 5 day period.

North America is the largest market for non-invasive prenatal testing. Emerging markets of Asia-Pacific and Latin America are growing at a significant growth rate, attributed by the growing awareness about chromosomal abnormalities, their prevention, growing population of late maternity age, and rapid development of healthcare infrastructure. However, ethical concerns associated with such tests is the most prominent market restraint.

The major players engaged in the global noninvasive prenatal testing market are LifeCodexx AG, Illumina, Inc., Sequenom, Inc. LABCORP, Natera, Inc. and others.

Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/57840

Table of Content

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

Chapter 2 Executive Summary
2.1 Non-Invasive Prenatal Testing Market, by Products, 2015 (USD Mn)
2.2 Non-Invasive Prenatal Testing Market Share, by Geography, 2015 (Value %)

Chapter 3 Non-Invasive Prenatal Testing Market: Market Dynamics and Outlook
3.1 Introduction
3.2 Major Commercial Events
3.3 Drivers
3.4 Challenges
3.5 Opportunities
3.6 Attractive Investment Proposition
3.1 Competitive Analysis: Fractal Map Investigation, by Key Market Players

Chapter 4 Global Non-Invasive Prenatal Testing Market Analysis, by Products
4.1 Preface
4.2 MaterniT21 PLUS
4.3 BambniTest
4.4 informaSeq Prenatal Test
4.5 Harmony Prenatal Test
4.6 Non-invasive Fetal Trisomy (NIFTY) Test
4.7 verifi
4.8 PrenaTest
4.9 Panorama Test
4.10 VisibiliT Test

Chapter 5 Global Non-Invasive Prenatal Testing Market, by Geography
5.1 Preface
5.2 North America
5.2.1 U.S.
5.2.2 Canada
5.3 Europe
5.3.1 U.K.
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia-Pacific
5.4.1 Japan
5.4.2 China
5.4.3 Rest of Asia-Pacific
5.5 Middle East and Africa (MEA)
5.6 Latin America

Chapter 6 Company Profiles
6.1 Ariosa Diagnostics, Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Positions/Portfolio
6.1.4 News Coverage
6.2 Berry Genomics Co., Ltd.
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Positions/Portfolio
6.2.4 News Coverage
6.3 BGI Diagnostics
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Positions/Portfolio
6.3.4 News Coverage
6.4 Illumina, Inc.
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Positions/Portfolio
6.4.4 News Coverage
6.5 Laboratory Corporation of America Holdings (LabCorp)
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Positions/Portfolio
6.5.4 News Coverage
6.6 LifeCodexx AG
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product Positions/Portfolio
6.6.4 News Coverage
6.7 Natera, Inc.
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Positions/Portfolio
6.7.4 News Coverage
6.8 Sequenom, Inc.
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Positions/Portfolio
6.8.4 News Coverage
6.9 Others
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Positions/Portfolio
6.9.4 News Coverage

Do Enquiry before Buying for research report: https://www.credenceresearch.com/inquiry-before-buying/57840

Welcome to a place where words matter. On Medium, smart voices and original ideas take center stage - with no ads in sight. Watch
Follow all the topics you care about, and we’ll deliver the best stories for you to your homepage and inbox. Explore
Get unlimited access to the best stories on Medium — and support writers while you’re at it. Just $5/month. Upgrade